135 related articles for article (PubMed ID: 9359711)
21. Synthesis, properties and applications of papillomavirus-like particles.
Sapp M; Volpers C; Streeck RE
Intervirology; 1996; 39(1-2):49-53. PubMed ID: 8957669
[TBL] [Abstract][Full Text] [Related]
22. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
[TBL] [Abstract][Full Text] [Related]
23. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.
Hunter Z; Tumban E; Dziduszko A; Chackerian B
Vaccine; 2011 Jun; 29(28):4584-92. PubMed ID: 21549786
[TBL] [Abstract][Full Text] [Related]
24. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
25. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
26. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.
Rose RC; Lane C; Wilson S; Suzich JA; Rybicki E; Williamson AL
Vaccine; 1999 Apr; 17(17):2129-35. PubMed ID: 10367945
[TBL] [Abstract][Full Text] [Related]
27. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
28. Immunological analyses of human papillomavirus capsids.
Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC
Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904
[TBL] [Abstract][Full Text] [Related]
29. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
30. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.
Rose RC; Reichman RC; Bonnez W
J Gen Virol; 1994 Aug; 75 ( Pt 8)():2075-9. PubMed ID: 8046412
[TBL] [Abstract][Full Text] [Related]
32. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.
Kim SN; Jeong HS; Park SN; Kim HJ
J Virol Methods; 2007 Jan; 139(1):24-30. PubMed ID: 17034867
[TBL] [Abstract][Full Text] [Related]
33. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles.
Marais D; Passmore JA; Maclean J; Rose R; Williamson AL
J Gen Virol; 1999 Sep; 80 ( Pt 9)():2471-2475. PubMed ID: 10501503
[TBL] [Abstract][Full Text] [Related]
34. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice.
Nardelli-Haefliger D; Roden R; Balmelli C; Potts A; Schiller J; De Grandi P
J Virol; 1999 Nov; 73(11):9609-13. PubMed ID: 10516071
[TBL] [Abstract][Full Text] [Related]
35. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles.
Palker TJ; Monteiro JM; Martin MM; Kakareka C; Smith JF; Cook JC; Joyce JG; Jansen KU
Vaccine; 2001 Jun; 19(27):3733-43. PubMed ID: 11395208
[TBL] [Abstract][Full Text] [Related]
36. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
37. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
38. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
[TBL] [Abstract][Full Text] [Related]
39. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.
Yao Q; Vuong V; Li M; Compans RW
Vaccine; 2002 Jun; 20(19-20):2537-45. PubMed ID: 12057610
[TBL] [Abstract][Full Text] [Related]
40. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
